Cancer Player Revolution Medicines Gets Bullish Rating: Here's Details
Portfolio Pulse from Vandana Singh
Raymond James initiated coverage on Revolution Medicines Inc (NASDAQ:RVMD) with an Outperform rating and a target price of $30. The optimism is based on the compelling October readout of RMC-6236, a first-in-class RAS(ON) inhibitor for treating cancers with common RAS mutations. Raymond James believes RVMD's technology can differentiate from other KRAS inhibitors and has a larger market potential. They also see a reasonable success probability for the planned Phase 3 studies of RMC-6236 in 2024.
November 16, 2023 | 8:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Revolution Medicines received an Outperform rating and a $30 target price from Raymond James, driven by the potential of its RMC-6236 cancer treatment and upcoming Phase 3 studies.
The Outperform rating and positive analyst coverage from Raymond James are likely to instill investor confidence in RVMD, potentially driving the stock price up in the short term. The target price of $30 suggests significant upside from the current price of $21.30. The analyst's mention of a 'reasonable probability of success' for the Phase 3 studies could further bolster investor sentiment.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100